Results 261 to 270 of about 29,467 (290)

Direct-acting antiviral retreatment patterns for hepatitis C

Journal of Managed Care & Specialty Pharmacy, 2022
BACKGROUND: Despite the strong efficacy of direct-acting antivirals (DAAs) against the hepatitis C virus, many patients require a second regimen of DAA treatment. However, limited research exists to characterize rates of retreatment across different DAA agents or potential factors that may increase retreatment risk.
Shaquib Al, Hasan, Daniel G, Dauner, Abhijeet, Rajpurohit, Joel F, Farley   +3 more
openaire   +2 more sources

Management of direct-acting antiviral agent failures

Journal of Hepatology, 2015
Failure to respond to the approved combinations of multiple direct-acting antiviral agents is relatively low in hepatitis C virus treatment registration studies, with rates of 1% to 7%, depending on the patients' baseline characteristics. In real life, failure is slightly higher, likely because of lower compliance.
Maria, Buti, Mar, Riveiro-Barciela, Rafael, Esteban   +2 more
openaire   +2 more sources

Chronic Hepatitis C and Direct Acting Antivirals

Surgical Pathology Clinics, 2018
The hepatitis C virus (HCV) is the most common blood-borne infection in the United States and is the most common cause of end-stage liver disease requiring liver transplant. Over the last 10 years, direct acting antiviral therapies have revolutionized HCV treatment, increasing the cure rates from less than 50% to more than 90% in those who reach access
Maria, Westerhoff, Joseph, Ahn
openaire   +2 more sources

Resistance to Direct-Acting Antivirals

Current Hepatitis Reports, 2012
Viral resistance corresponds to the selection, during treatment, of pre-existing viral variants less susceptible to the drug’s inhibitory activity because they bear amino acid substitutions altering the drug target. Hepatitis C virus (HCV) drugs in development can be split into two groups according to their barrier to resistance.
openaire   +1 more source

Resistance to direct-acting antiviral agents

Current Opinion in HIV and AIDS, 2015
This article examines the dynamics and factors underlying hepatitis C virus (HCV) resistance, along with their impact on daily clinical management of HCV-infected patients.Across available treatment-regimens, GT-3 is the most difficult-to-cure genotype, but also genotype-1a may show lower success-rates compared with genotype-1b.
Valeria, Cento, Stephane, Chevaliez, Carlo Federico, Perno   +2 more
openaire   +2 more sources

Benefits of Direct-Acting Antivirals for Hepatitis C

Annals of Internal Medicine, 2017
Emerging data show that direct-acting antivirals (DAAs) improve clinical outcomes in hepatitis C virus (HCV).
Anna S, Lok, Raymond T, Chung, Hugo E, Vargas, Arthur Y, Kim, Susanna, Naggie, William G, Powderly   +5 more
openaire   +2 more sources

Direct acting antiviral therapy after liver transplantation

Current Opinion in Gastroenterology, 2016
Historically, postliver transplant patients with chronic hepatitis C have had worse outcomes than nonhepatitis C-related causes because of accelerated fibrosis posttransplantation and the lack of effective well tolerated therapies for hepatitis C, and posttransplant hepatitis C patients have been considered a special population.
openaire   +2 more sources

Direct acting antivirals failure: cause and retreatment options

Expert Review of Gastroenterology & Hepatology, 2018
Chronic hepatitis C (HCV) infection is a systemic life-threatening condition that can lead to hepatic and extra-hepatic complications. Sustained virological response (SVR) is associated with a regression of most liver and non-liver manifestations, which reduce mortality.
Lucia, Parlati, Stanislas, Pol
openaire   +2 more sources

[Direct-acting antiviral-resistant variant].

Nihon rinsho. Japanese journal of clinical medicine, 2015
Recently, IFN-free NS5A inhibitor daclatasvir and protease inhibitor asunaprevir combination treatment was approved for genotype 1b HCV-infected patients who were ineligible or who failed to respond to previous therapies. NS5A inhibitor-resistant variants occasionally exist in HCV-infected patients who have never been exposed to direct-acting ...
Michio, Imamura, Kazuaki, Chayama
openaire   +1 more source

Controversies of Direct-Acting Antivirals in Hepatocellular Carcinoma

Surgical Oncology Clinics of North America
Therapy for chronic hepatitis C virus infection with direct-acting antiviral agents (DAAs) has been highly successful in achieving sustained virological response (SVR) with associated improvements in liver dysfunction, liver-related mortality, and transplant-free survival.
Ifrah, Fatima, Neehar D, Parikh, Alisa, Likhitsup   +2 more
openaire   +2 more sources